Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling

BACKGROUND: Anti TNF drugs have been widely used in rheumatoid arthritis (RA) but only 70 to 80 % of patients respond to this therapy. Exploring the mode of action of anti-TNF drugs remains important in order to improve the efficiency of the treatment and enhance our knowledge of inflammation. TNF-α...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Arthritis Res Ther
Egile Nagusiak: Boyer, Jean Frédéric, Baron, Michel, Constantin, Arnaud, Degboé, Yannick, Cantagrel, Alain, Davignon, Jean-Luc
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4774095/
https://ncbi.nlm.nih.gov/pubmed/26932562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-0955-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak